ABT is trading at $106.93, down 11.4%, following disappointing fourth-quarter earnings where revenue missed consensus and Q1 2026 guidance fell short of analyst expectations.
- While Abbott matched EPS estimates at $1.50, reported revenue of $11.46 billion fell short of the $11.8 billion consensus.
- The sharp selloff was driven primarily by the company issuing Q1 2026 guidance ($1.12-$1.18 EPS) which missed the $1.20 analyst expectation.
- Nutrition sales declined 8.9% and Diagnostics fell 2.5%, contrasting with double-digit growth seen in Medical Devices and Diabetes Care segments.